Lori Fulton, MD
Obstetrics & Gynecology · Jackson, MSNPI 1427149582
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,200 of the $102,164 with a category attached, or 81.4%. Astellas Pharma US Inc accounts for 82.3% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $58,026, more than ten times the $434 reported in 2019. Among obstetrics & gynecology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $316.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$84K
- CMR Surgical, Inc.$13K
- Axonics, Inc.$2K
- AbbVie$676
- Sumitomo Pharma America, Inc.$511
- Therapeuticsmd, Inc.$230
- plus $1K from 27 others
What the payments were for
- Speaking & faculty fees$83,20081%
- Travel & lodging$11,13911%
- Food & beverage$7,7078%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 128 | $84,106 |
| CMR Surgical, Inc. | 14 | $13,437 |
| Axonics, Inc. | 32 | $1,943 |
| AbbVie(2 entities) | 38 | $676 |
| Sumitomo Pharma America, Inc. | 25 | $511 |
| Therapeuticsmd, Inc. | 14 | $230 |
| Exeltis, USA Inc. | 13 | $218 |
| Pfizer | 6 | $108 |
| Mayne Pharma Commercial LLC | 9 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Astellas Pharma Global Development | 3 | $93 |
| Urovant Sciences Inc | 5 | $85 |
| Novo Nordisk | 3 | $47 |
| Aspira Women's Health Inc | 1 | $44 |
| Currax Pharmaceuticals LLC | 3 | $44 |
| Medline Industries LP | 2 | $44 |
| Lupin Inc. | 3 | $35 |
| Avion Pharmaceuticals | 3 | $34 |
| Acella Pharmaceuticals, LLC | 2 | $32 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Vertical Pharmaceuticals, LLC | 1 | $24 |
| Abbott | 1 | $24 |
| Innovation Technologies Inc | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Provepharm Inc. | 1 | $21 |
| BD | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Coopersurgical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$82,548
- Versius Surgical System (Versius Plus)$13,173
- Axonics r-SNM System$823
- Bulkamid$720
- Axonics$613
How this compares
$102,164 in reported general payments places this provider in the 95th percentile of 318 obstetrics & gynecology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $11,806 |
| Estradiol | 247 | $9,200 |
| PremarinEstrogens, Conjugated | 23 | $7,447 |
| ValacyclovirValacyclovir Hcl | 71 | $2,190 |
| Estradiol (Twice Weekly)Estradiol | 28 | $1,283 |
| Clobetasol Propionate | 29 | $1,062 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 12 | $1,061 |
| NitrofurantoinNitrofurantoin Macrocrystal | 22 | $698 |
| ProgesteroneProgesterone, Micronized | 14 | $600 |
| Raloxifene Hcl | 21 | $407 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $278 |
| Medroxyprogesterone Acetate | 13 | $258 |
| SprintecNorgestimate-Ethinyl Estradiol | 11 | $207 |
| Fluconazole | 28 | $145 |
| Nystatin | 11 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $84,106 | $11,80617 claims |
| PfizerPremarin | $108 | $7,44723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 318 obstetrics & gynecology providers in Mississippi.
Other obstetrics & gynecology in Jackson
- Sheila BouldinJackson$56K
- Fred IngramJackson$8K
- Jennifer MosesJackson$8K
- Kathryn JeromeJackson$8K
- John WooleyJackson$7K
- Erica OryJackson$6K
- Amanda NicolsJackson$6K
- Leland GebhartJackson$5K
- Meredith TravelsteadJackson$5K
- Jesse EthridgeJackson$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.